Literature DB >> 6498616

A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.

T Inaba, M Nakano, S V Otton, W A Mahon, W Kalow.   

Abstract

The present study compares the debrisoquine monooxygenase and the sparteine monooxygenase activities of human liver microsomes. In the presence of 14 competitive inhibitors, apparent inhibition constants (Ki) as determined by these two activities ranged over four orders of magnitude with a correlation coefficient 0.99. These in vitro results represent the strongest evidence to date that the debrisoquine monooxygenase and the sparteine monooxygenase are identical and involve a single isozyme of cytochrome P-450.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6498616     DOI: 10.1139/y84-144

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  11 in total

1.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.

Authors:  M D Nielsen; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

2.  Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.

Authors:  G Mikus; H R Ha; S Vozeh; C Zekorn; F Follath; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 4.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

5.  Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.

Authors:  S Wanwimolruk; S Chalcroft
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 6.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

Authors:  F Nielsen; J U Rosholm; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

Review 9.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

10.  Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

Authors:  K Brøsen; F Davidsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.